Source comparison
MOTS-C Nasal Spray: Research Applications vs Clinical Use
Primary Mechanism AMPK activation → fatty acid oxidation, mitochondrial biogenesis, insulin sensitization Improved HOMA-IR, reduced fasting insulin, enhanced glucose disposal during OGTT Not FDA-approved for therapeutic use; available for research under invest
This comparison does not assign a generated winner or score.
- Primary Mechanism
- AMPK activation → fatty acid oxidation, mitochondrial biogenesis, insulin sensitization
- Improved HOMA-IR, reduced fasting insulin, enhanced glucose disposal during OGTT
- Not FDA-approved for therapeutic use; available for research under investigational protocols
- Mechanism is well-characterized in animal models; human data limited but consistent with preclinical findings
- Dosing Range
- 5–15 mg/kg in mice (translates to ~50–200 mcg human equivalent)
- 100–200 mcg nasal spray once daily
- No standardized clinical dosing protocol exists
- Pilot data supports 100–200 mcg daily; long-term safety beyond 12 weeks not yet established
- Primary Outcomes
- Prevention of diet-induced obesity, 35% reduction in fasting glucose, 40% improvement in insulin sensitivity
- 28% reduction in fasting insulin (200 mcg group), no hypoglycemia, mild nasal irritation in 12%
- No FDA-approved indications; used in metabolic research and longevity studies
- Human data aligns with preclinical efficacy; larger RCTs needed for clinical validation
- Route Comparison
- Subcutaneous injection (100% bioavailability), nasal spray (60–70%), oral (negligible due to GI degradation)
- Nasal spray preferred for convenience and non-invasive delivery
- Nasal formulations avoid hepatic first-pass metabolism
- Nasal bioavailability sufficient for metabolic effects; subcutaneous may offer higher peak concentrations but requires injection